NasdaqGS - Delayed Quote USD

Relmada Therapeutics, Inc. (RLMD)

3.8300 +0.1300 (+3.51%)
At close: April 26 at 4:00 PM EDT
3.8300 0.00 (0.00%)
After hours: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
103,702.2930
103,702.2930
161,249.0760
125,703.4920
60,838.6730
Operating Income
-103,702.2930
-103,702.2930
-161,249.0760
-125,703.4920
-60,838.6730
Net Non Operating Interest Income Expense
5,151.7040
5,151.7040
2,659.4240
1,199.0770
1,399.2250
Other Income Expense
-241.1570
-241.1570
1,545.8290
-1,247.3940
-16.9460
Pretax Income
-98,791.7460
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Net Income Common Stockholders
-98,791.7460
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Diluted NI Available to Com Stockholders
-98,791.7460
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Basic EPS
-3.28
-3.28
-5.30
-7.16
-3.81
Diluted EPS
-3.28
-3.28
-5.30
-7.16
-3.81
Basic Average Shares
30,099.2030
30,099.2030
29,628.6640
17,552.7380
15,594.2280
Diluted Average Shares
30,099.2030
30,099.2030
29,628.6640
17,552.7380
15,594.2280
Total Operating Income as Reported
-103,702.2930
-103,702.2930
-161,249.0760
-125,703.4920
-60,838.6730
Total Expenses
103,702.2930
103,702.2930
161,249.0760
125,703.4920
60,838.6730
Net Income from Continuing & Discontinued Operation
-98,791.7460
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Normalized Income
-98,550.5890
-98,550.5890
-152,238.0460
-124,504.4150
-59,439.4480
Interest Income
5,151.7040
5,151.7040
2,659.4240
1,199.0770
1,399.2250
Net Interest Income
5,151.7040
5,151.7040
2,659.4240
1,199.0770
1,399.2250
EBIT
-103,702.2930
-103,702.2930
-161,249.0760
-125,703.4920
-60,838.6730
EBITDA
-103,702.2930
-103,702.2930
-161,249.0760
-125,702.2340
-60,834.9210
Reconciled Depreciation
--
--
--
1.2580
3.7520
Net Income from Continuing Operation Net Minority Interest
-98,791.7460
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Total Unusual Items Excluding Goodwill
-241.1570
-241.1570
-4,805.7770
-1,247.3940
-16.9460
Total Unusual Items
-241.1570
-241.1570
-4,805.7770
-1,247.3940
-16.9460
Normalized EBITDA
-103,461.1360
-103,461.1360
-156,443.2990
-124,454.8400
-60,817.9750
12/31/2020 - 6/20/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BCTXW BriaCell Therapeutics Corp.
0.9375
+0.27%
 
LRMR Larimar Therapeutics, Inc.
6.44
+1.74%
 
VRCA Verrica Pharmaceuticals Inc.
6.87
+3.31%
 
INZY Inozyme Pharma, Inc.
4.4400
+2.54%
 
MREO Mereo BioPharma Group plc
2.7400
-2.49%
 
LIFE aTyr Pharma, Inc.
1.5700
-1.57%
 
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
 
ARMP Armata Pharmaceuticals, Inc.
2.7600
+9.06%
 
SPRB Spruce Biosciences, Inc.
0.7000
-0.14%
 
NVCT Nuvectis Pharma, Inc.
6.50
-0.15%